详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A novel serum m7G-harboring microRNA signature for cancer detection

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Jiujiang First People's Hospital, Jiujiang, Jiangxi, China. [3]Center of Growth, Metabolism, and Aging, Key Laboratory of Bio-Resources and Eco-Environment, College of Life Sciences, Sichuan University, Chengdu, Sichuan, China.

出处：

DOI：

ISSN：

关键词： m7G microRNA liquid biopsy cancer diagnosis pan-cancer

摘要：

Background: Emerging evidence points to the exceptional importance and value of m7G alteration in the diagnosis and prognosis of cancers. Nonetheless, a biomarker for precise screening of various cancer types has not yet been developed based on serum m7G-harboring miRNAs. Methods: A total of 20,702 serum samples, covering 12 cancer types and consisting of 7,768 cancer samples and 12,934 cancer-free samples were used in this study. A m7G target miRNA diagnostic signature (m7G-miRDS) was established through the least absolute shrinkage and selection operator (LASSO) analyses in a training dataset (n = 10,351), and validated in a validation dataset (n = 10,351). Results: The m7G-miRDS model, a 12 m7G-target-miRNAs signature, demonstrated high accuracy and was qualified for cancer detection. In the training and validation cohort, the area under the curve (AUC) reached 0.974 (95% CI 0.971-0.977) and 0.972 (95% CI 0.969-0.975), respectively. The m7G-miRDS showed superior sensitivity in each cancer type and had a satisfactory AUC in identifying bladder cancer, lung cancer and esophageal cancer. Additionally, the diagnostic performance of m7G-miRDS was not interfered by the gender, age and benign disease. Conclusion: Our results greatly extended the value of serum circulating miRNAs and m7G in cancer detection, and provided a new direction and strategy for the development of novel biomarkers with high accuracy, low cost and less invasiveness for mass cancer screening, such as ncRNA modification.Copyright © 2024 Chen, Xie, Bi, Ci, Li and Liu.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区生物学

小类 | 3 区遗传学

最新[2023]版：

大类 | 3 区生物学

小类 | 3 区遗传学

第一作者：

第一作者机构： [1]Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification. [2]A review on interplay between small RNAs and oxidative stress in cancer progression. [3]Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases [4]Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. [5]Quality Materials for Quality Assurance in the Analysis of Liquid Biopsy Samples [6]Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine [7]Droplet digital PCR-based circulating microRNA detection serve as a promising diagnostic method for gastric cancer [8]A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel [9]Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application [10]基于肿瘤教化血小板的液体活检研究进展